Markets:

Overview

News

Currencies

International

Treasuries

Regeneron Pharmaceuticals (NQ:REGN)

769.64 +20.36 (+2.72%)

Streaming Delayed Price Updated: 2:58 PM EDT, Mar 31, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Regeneron Pharmaceuticals

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

60 61 Next >

IBD's 100 Best ESG Companies For 2023 ↗

October 27, 2023

The companies on our list combine high sustainability scores and top stock ratings.

Via Investor's Business Daily

$100 Invested In This Stock 20 Years Ago Would Be Worth $6,000 Today ↗

October 19, 2023

Via Benzinga

Price Over Earnings Overview: Regeneron Pharmaceuticals ↗

October 17, 2023

Via Benzinga

The Latest Analyst Ratings for Regeneron Pharmaceuticals ↗

October 11, 2023

Via Benzinga

Down 45%, Is Intellia a Buy? ↗

October 10, 2023

Intellia's operating in the high-growth field of gene editing.

Via The Motley Fool

Apple, AMD, Palantir Earnings On Deck This Week As Market Seeks Positive Catalysts In Fed Decision Week ↗

October 30, 2023

S&P 500 earnings is expected to grow in Q3, reversing a four-quarter slide, as the reporting season enters its third week.

Via Benzinga

Topics Economy Stocks

Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More ↗

October 28, 2023

The U.S.

Via Benzinga

SNY Stock Sinks 15% as Sanofi Plans Consumer Unit Spinoff ↗

October 27, 2023

The happy talk in Sanofi's press release didn't help with analysts, who have been disappointed in the company and SNY stock all year.

Via InvestorPlace

Regeneron Shares Preliminary Results Showing Gene Therapy Improves Auditory Responses in Child with Profound Genetic Hearing Loss

October 26, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Regeneron Announces Investor Conference Presentations

October 25, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

P/E Ratio Insights for Regeneron Pharmaceuticals ↗

October 06, 2023

Via Benzinga

Stock-Split Watch: Could These 2 Growth Stocks Be Next? ↗

October 25, 2023

Neither company has discussed it, at least not yet.

Via The Motley Fool

Global Cancer Vaccines Market Share Is Expected To Reach $19.27 Billion By 2030

October 25, 2023

EQNX::TICKER_START (OTCPK:DTCFF),(CSE:DTC),(NASDAQ:JAZZ),(NASDAQ:EXEL),(NASDAQ:AMGN),(NASDAQ:REGN) EQNX::TICKER_END

Via FinancialNewsMedia

Dupixent® (dupilumab) Phase 3 Results Show Sustained Efficacy for Up to One Year in Children 1 to 11 Years of Age with Eosinophilic Esophagitis (EoE)

October 22, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Libtayo® (cemiplimab) Neoadjuvant Treatment Demonstrates Encouraging Event-Free Survival in Patients with Resectable Cutaneous Squamous Cell Carcinoma (CSCC)

October 21, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Which Is the Better Long-Term Hold for Investors: Pfizer or Roche? ↗

October 21, 2023

The venerable pharmaceutical companies' shares have slumped this year.

Via The Motley Fool

Regeneron and Sanofi Provide Update on Dupixent® (dupilumab) sBLA for Chronic Spontaneous Urticaria

October 20, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

10 Health Care Stocks Whale Activity In Today's Session ↗

October 18, 2023

Via Benzinga

Intellia Stumbles As It Aims For A First-Ever In CRISPR Gene Editing ↗

October 18, 2023

The company can begin a pivotal study of its treatment for cardiomyopathy.

Via Investor's Business Daily

Regeneron builds on Together for CHANGE™ initiative with five-year, $5 million commitment to fuel the STEM talent pipeline in Nashville, TN

October 18, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Together for CHANGE Genomics and Equity Initiative Launched by a Coalition of Meharry Medical College, Regeneron Genetics Center, AstraZeneca, Novo Nordisk, and Roche to Improve Health Outcomes for People of African Ancestry

October 18, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

Why REGENERON PHARMACEUTICALS (NASDAQ:REGN) Deserves Consideration as a Quality Investment. ↗

October 17, 2023

This article explores why quality investors may have a look at REGENERON PHARMACEUTICALS (NASDAQ:REGN)

Via Chartmill

Healthcare Portfolio Focus Stocks ↗

October 16, 2023

The macro news has been a steady headwind with rising rates offering 5% risk-free treasury yields.

Via Talk Markets

Cantor Fitzgerald Maintains Neutral Rating for Regeneron Pharmaceuticals: Here's What You Need To Know ↗

October 16, 2023

Via Benzinga

2 Healthcare Stocks Near 52-Week Highs Still Worth Buying ↗

October 16, 2023

These two large-cap biopharma companies could have more room to run.

Via The Motley Fool

Regeneron to Showcase Progress from Innovative Oncology Portfolio in Several Difficult-to-Treat Cancers at ESMO

October 15, 2023

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

AI Stocks AVGO And ANET Lead 5 Resilient Names Near Buy Points ↗

October 14, 2023

Broadcom and Arista lead five stocks sporting a flat base.

Via Investor's Business Daily

Topics Artificial Intelligence

Large Cap Biopharmaceuticals-Core Holdings For Your Healthcare Portfolio Until M&A Action Picks Up ↗

October 09, 2023

Healthcare has not been a strong sector in 2023. Despite its history of being defensive in turbulent times the sector has underperformed as higher rates curb buyers sentiment.

Via Talk Markets

Biotech Sector: On The Verge Of Triumph Or Turmoil? ↗

October 06, 2023

In this article, we delve into the Biotech Sector, exploring its promises, potential pitfalls, and the questions that arise.

Via Talk Markets

EYLEA® HD (aflibercept) Injection 8 mg Two-year Results from Pivotal PULSAR Trial in Wet Age-related Macular Degeneration Presented at EURETINA

October 05, 2023

First presentation of long-term results demonstrated sustained visual and anatomic improvements among EYLEA HD patients through two years

From Regeneron Pharmaceuticals, Inc.

Via GlobeNewswire

< Previous 1 2

...

28 29 30 31 32 33 34 35 36

...

60 61 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.